NCT00141479

To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

A Single-center Safety and Tolerability Study to Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: —
• Sponsor: Solvay Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.

Conditions

• Schizophrenia
• Schizoaffective Disorder

Interventions

Type	Name	Description
DRUG	Bifeprunox

Timeline

• Start date: 2005-05-01
• Primary completion: 2006-11-01
• Completion: 2006-11-01
• First posted: 2005-09-01
• Last updated: 2015-01-16

Locations

1 site across 1 country: United States